Your browser doesn't support javascript.
loading
The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease.
Mäkitalo, Signar; Mellgren, Åsa; Borgh, Ellen; Kilander, Lena; Skillbäck, Tobias; Zetterberg, Henrik; Gisslén, Magnus.
Afiliação
  • Mäkitalo S; Department of Infectious Diseases, Gävle Hospital, Gävle, Sweden.
  • Mellgren Å; Clinic of Infectious Diseases, South Älvsborg Hospital, Borås, Sweden ; Department of Infectious Diseases, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Borgh E; Department of Respiratory Medicine, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Kilander L; Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.
  • Skillbäck T; Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Zetterberg H; Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden ; UCL Institute of Neurology, Queen Square, London, UK.
  • Gisslén M; Department of Infectious Diseases, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
AIDS Res Ther ; 12: 23, 2015.
Article em En | MEDLINE | ID: mdl-26175795
ABSTRACT
It is a challenge to differentiate between HIV-associated neurocognitive disorders (HAND) and other types of neurocognitive disease in the ageing HIV-infected population. Here we describe a 63 year old HIV-infected woman who had a history, neuropsychological test result, and PET examination consistent with characteristic Alzheimer's disease (AD). The cerebrospinal fluid (CSF) biomarker profile was analogous to the profile typically found in AD in HIV-negative patients with increased t-tau and p-tau, a decreased level of Aß42 and normal levels of CSF neurofilament light protein and sAPPα and sAPPß, distinctly different from findings in HIV-associated dementia (HAD). Assessment of CSF biomarkers may be a valuable tool for clinicians to distinguish between HAD and AD.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article